share_log

Loss-making DENTSPLY SIRONA (NASDAQ:XRAY) Sheds a Further US$273m, Taking Total Shareholder Losses to 42% Over 3 Years

Loss-making DENTSPLY SIRONA (NASDAQ:XRAY) Sheds a Further US$273m, Taking Total Shareholder Losses to 42% Over 3 Years

亏损的DENTSPLY SIRONA(纳斯达克股票代码:XRAY)又下跌2.73亿美元,使股东损失总额在3年内达到42%
Simply Wall St ·  2023/11/10 10:20

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long term DENTSPLY SIRONA Inc. (NASDAQ:XRAY) shareholders have had that experience, with the share price dropping 44% in three years, versus a market return of about 16%. The falls have accelerated recently, with the share price down 30% in the last three months. We note that the company has reported results fairly recently; and the market is hardly delighted. You can check out the latest numbers in our company report.

为了证明选择个股的努力是合理的,值得努力击败市场指数基金的回报。但是,如果你尝试选股,你的风险回报将小于市场。我们遗憾地报告,DENTSPLY SIRONA Inc.(纳斯达克股票代码:XRAY)的长期股东也有这样的经历,股价在三年内下跌了44%,而市场回报率约为16%。最近,跌幅加快,股价在过去三个月中下跌了30%。我们注意到,该公司最近才公布业绩;市场对此并不满意。您可以在我们的公司报告中查看最新数字。

Since DENTSPLY SIRONA has shed US$273m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由于DENTSPLY SIRONA在过去7天内贬值了2.73亿美元,让我们看看长期下跌是否是由该公司的经济推动的。

See our latest analysis for DENTSPLY SIRONA

查看我们对 DENTSPLY SIRONA 的最新分析

DENTSPLY SIRONA isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

DENTSPLY SIRONA目前没有盈利,因此大多数分析师会关注收入增长,以了解基础业务的增长速度。一般而言,没有利润的公司预计每年都会以不错的速度增长收入。那是因为可以很容易地推断出快速的收入增长来预测利润,而利润通常规模相当大。

In the last three years, DENTSPLY SIRONA saw its revenue grow by 4.1% per year, compound. That's not a very high growth rate considering it doesn't make profits. Indeed, the stock dropped 13% over the last three years. If revenue growth accelerates, we might see the share price bounce. But ultimately the key will be whether the company can become profitability.

在过去的三年中,DENTSPLY SIRONA的收入每年增长4.1%。考虑到它不赚钱,这并不是一个很高的增长率。事实上,该股在过去三年中下跌了13%。如果收入增长加速,我们可能会看到股价反弹。但归根结底,关键将是公司能否盈利。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。

earnings-and-revenue-growth
NasdaqGS:XRAY Earnings and Revenue Growth November 10th 2023
纳斯达克:Xray 收益和收入增长 2023 年 11 月 10 日

We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling DENTSPLY SIRONA stock, you should check out this free report showing analyst profit forecasts.

我们喜欢内部人士在过去十二个月中一直在购买股票。即便如此,未来的收益对于当前股东是否赚钱将更为重要。如果您正在考虑买入或卖出DENTSPLY SIRONA股票,则应查看这份显示分析师利润预测的免费报告。

A Different Perspective

不同的视角

While the broader market gained around 9.8% in the last year, DENTSPLY SIRONA shareholders lost 8.6% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with DENTSPLY SIRONA , and understanding them should be part of your investment process.

尽管去年整个市场上涨了约9.8%,但DENTSPLY SIRONA的股东却下跌了8.6%(甚至包括股息)。即使是优质股票的股价有时也会下跌,但我们希望看到企业的基本指标有所改善,然后才会变得过于感兴趣。令人遗憾的是,去年的业绩结束了糟糕的表现,股东们在五年内每年面临4%的总亏损。我们意识到,罗斯柴尔德男爵曾说过,投资者应该 “在街头流血时买入”,但我们警告说,投资者应首先确保他们购买的是高质量的企业。我发现从长远来看,将股价视为业务表现的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,以永远存在的投资风险幽灵为例。我们已经发现了DENTSPLY SIRONA的1个警告信号,理解这些信号应该成为您投资过程的一部分。

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

还有很多其他公司有内部人士购买股票。你可能不想错过这份业内人士正在收购的成长型公司的免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发